Cargando…

Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study

Endovenous thermal methods are superseding surgical stripping for treating chronic superficial venous disease but require tumescent anesthesia and can cause heat-related nerve injuries. Endovenous cyanoacrylate ablation is a more recent technique that does not share these drawbacks. A retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Falvo, Nicolas, Latreche, Amine, Chevallier, Olivier, Ledan, Frédérik, Jandot, Maud, Daoud, Héla, Fréchier, Léo, Loffroy, Romaric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377952/
https://www.ncbi.nlm.nih.gov/pubmed/37510057
http://dx.doi.org/10.3390/diagnostics13142313
_version_ 1785079645296656384
author Falvo, Nicolas
Latreche, Amine
Chevallier, Olivier
Ledan, Frédérik
Jandot, Maud
Daoud, Héla
Fréchier, Léo
Loffroy, Romaric
author_facet Falvo, Nicolas
Latreche, Amine
Chevallier, Olivier
Ledan, Frédérik
Jandot, Maud
Daoud, Héla
Fréchier, Léo
Loffroy, Romaric
author_sort Falvo, Nicolas
collection PubMed
description Endovenous thermal methods are superseding surgical stripping for treating chronic superficial venous disease but require tumescent anesthesia and can cause heat-related nerve injuries. Endovenous cyanoacrylate ablation is a more recent technique that does not share these drawbacks. A retrospective observational study of consecutive adults managed with endovenous cyanoacrylate was conducted in 2018–2021 at a single university center. The follow-up was 18 months. We identified factors associated with target vein closure at 18 months and measured changes in quality of life using the generic 36-item Short-Form (SF-36) tool and the venous disease-specific VEINES-QOL/Sym questionnaire. Adverse events were collected. In the 55 study patients with 67 treated veins, the closure rate at 18 months was 94% (95% CI, 85–98%). Target vein diameter ≥9.5 mm had 81% sensitivity and 75% specificity for predicting recanalization. Quality-of-life scores improved significantly (p < 0.001 for both surveys). The only adverse event was a type IV allergic reaction to cyanoacrylate that was resolved with corticosteroid and histamine-antagonist therapy. Endovenous cyanoacrylate ablation was highly effective and is safe in experienced hands. Studies are warranted to determine whether changes in the protocol increase the closure rate in patients with target veins ≥9.5 mm in diameter.
format Online
Article
Text
id pubmed-10377952
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103779522023-07-29 Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study Falvo, Nicolas Latreche, Amine Chevallier, Olivier Ledan, Frédérik Jandot, Maud Daoud, Héla Fréchier, Léo Loffroy, Romaric Diagnostics (Basel) Article Endovenous thermal methods are superseding surgical stripping for treating chronic superficial venous disease but require tumescent anesthesia and can cause heat-related nerve injuries. Endovenous cyanoacrylate ablation is a more recent technique that does not share these drawbacks. A retrospective observational study of consecutive adults managed with endovenous cyanoacrylate was conducted in 2018–2021 at a single university center. The follow-up was 18 months. We identified factors associated with target vein closure at 18 months and measured changes in quality of life using the generic 36-item Short-Form (SF-36) tool and the venous disease-specific VEINES-QOL/Sym questionnaire. Adverse events were collected. In the 55 study patients with 67 treated veins, the closure rate at 18 months was 94% (95% CI, 85–98%). Target vein diameter ≥9.5 mm had 81% sensitivity and 75% specificity for predicting recanalization. Quality-of-life scores improved significantly (p < 0.001 for both surveys). The only adverse event was a type IV allergic reaction to cyanoacrylate that was resolved with corticosteroid and histamine-antagonist therapy. Endovenous cyanoacrylate ablation was highly effective and is safe in experienced hands. Studies are warranted to determine whether changes in the protocol increase the closure rate in patients with target veins ≥9.5 mm in diameter. MDPI 2023-07-08 /pmc/articles/PMC10377952/ /pubmed/37510057 http://dx.doi.org/10.3390/diagnostics13142313 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Falvo, Nicolas
Latreche, Amine
Chevallier, Olivier
Ledan, Frédérik
Jandot, Maud
Daoud, Héla
Fréchier, Léo
Loffroy, Romaric
Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study
title Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study
title_full Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study
title_fullStr Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study
title_full_unstemmed Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study
title_short Cyanoacrylate Glue for Treating Chronic Saphenous Vein Insufficiency: A Retrospective Observational Single-Center Study
title_sort cyanoacrylate glue for treating chronic saphenous vein insufficiency: a retrospective observational single-center study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377952/
https://www.ncbi.nlm.nih.gov/pubmed/37510057
http://dx.doi.org/10.3390/diagnostics13142313
work_keys_str_mv AT falvonicolas cyanoacrylategluefortreatingchronicsaphenousveininsufficiencyaretrospectiveobservationalsinglecenterstudy
AT latrecheamine cyanoacrylategluefortreatingchronicsaphenousveininsufficiencyaretrospectiveobservationalsinglecenterstudy
AT chevallierolivier cyanoacrylategluefortreatingchronicsaphenousveininsufficiencyaretrospectiveobservationalsinglecenterstudy
AT ledanfrederik cyanoacrylategluefortreatingchronicsaphenousveininsufficiencyaretrospectiveobservationalsinglecenterstudy
AT jandotmaud cyanoacrylategluefortreatingchronicsaphenousveininsufficiencyaretrospectiveobservationalsinglecenterstudy
AT daoudhela cyanoacrylategluefortreatingchronicsaphenousveininsufficiencyaretrospectiveobservationalsinglecenterstudy
AT frechierleo cyanoacrylategluefortreatingchronicsaphenousveininsufficiencyaretrospectiveobservationalsinglecenterstudy
AT loffroyromaric cyanoacrylategluefortreatingchronicsaphenousveininsufficiencyaretrospectiveobservationalsinglecenterstudy